Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Selvita SA

www.selvita.com

Latest From Selvita SA

Inflection's Lead Series Boosts AUM's Oncology Pipeline

Asian oncology venture gains worldwide rights to novel molecule series from Inflection, giving a leg up to its global ambitions.

Deals Cancer

Venture Funding Deals: I-Mab Is The Mega-Round Leader With $220m Series C

Freeline Therapeutics, I-Mab Biopharma, Kaleido Biosciences and Precision BioSciences raised more than $100m each, but Chinese start-ups continue to bring in some of this year's largest venture capital mega rounds, with $220m in Series C cash to fund development of immuno-oncology and inflammatory disease drug candidates.

Financing StartUps and SMEs

Appointments: Stada, Astellas, Novo Nordisk, Boehringer Ingelheim, Dova, Selvita, Orchard, MannKind, Cancer Genetics

The latest biopharma industry appointments include CEOs for Stada and Astellas, a finance chief for Novo Nordisk and a new president for Boehringer Ingelheim in the US, while Orchard Therapeutics has made a key addition to its scientific advisory board.

Appointments BioPharmaceutical

Deals Shaping The Medical Industry, April 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2017.

Deals BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Eastern Europe
        • Poland
  • Parent & Subsidiaries
  • Selvita SA
  • Senior Management
  • Pawel Przewiezlikowski , CEO
    Boguslaw Sieczkowski , EVP, COO
    Krzysztof Brzozka, PhD, EVP, CSO
    Setareh Shamsili, MD, PhD, CMO
  • Contact Info
  • Selvita SA
    Phone: 12 297 47 00
    Park Life Science, Bobrzynskiego 14
    Krakow, 30-348
    Poland
Advertisement
Advertisement
UsernamePublicRestriction

Register